Fast Track Group FTRK 深 滬
已收盤 02-06 16:00:00 美东时间
0.525
-0.040
-7.08%
華盛通- 最 高0.6171
- 今 開0.4888
- 成交量 3.31万股
- 最 低 0.48
- 昨 收 0.565
- 總市值 1145.16万
- 52周最高 9.69
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 0.2916
- 委 比 -98.53%
- 總股本 2181.25万
- 歷史最高 9.69
- 量 比 1.63
- 振 幅 24.27%
- 歷史最低 0.2916
- 每 手 1
- 風險率 1.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Bayer Asundexian Granted Fast Track Designation By FDA
BRIEF-Bayer Asundexian Granted Fast Track Designation By FDA Feb 5 (Reuters) - Bayer AG BAYGn.DE : ASUNDEXIAN SHOWS 26% REDUCTION IN STROKE RISK NO INCREASE IN ISTH MAJOR BLEEDING WITH ASUNDEXIAN ASUNDEXIAN GRANTED FAST TRACK DESIGNATION BY FDA Source text: ID:nBw2DLYMwa Further company coverage: [B
02-06 01:16
DXC Technology Co. Publishes Transcript of Third Quarter Fiscal 2026 Earnings Conference Call
DXC Technology Co. Publishes Transcript of Third Quarter Fiscal 2026 Earnings Conference Call DXC Technology Co. has published the transcript of its third quarter Fiscal 2026 earnings conference call. The event featured remarks from company leadership, including the President and Chief Executive Off
02-04 05:43
Sellas Life Sciences Group Showcases Novel Therapies Targeting Acute Myeloid Leukemia in Latest Corporate Presentation
Sellas Life Sciences Group Showcases Novel Therapies Targeting Acute Myeloid Leukemia in Latest Corporate Presentation Sellas Life Sciences Group Inc. presented updates on its two clinical-stage assets, Galinpepimut-S (GPS) and SLS009, both being developed for acute myeloid leukemia (AML). The Phase
02-04 05:19
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics granted 6,600 stock options to a new employee under its 2025 Inducement Plan, with a $5.84 exercise price per share. The options vest 25% after the first year and the remaining 75% over three years, contingent on continued employment. The company focuses on developing multimodal biological immunotherapies for cancer, with key products including aglatimagene (CAN-2409) and linoserpaturev (CAN-3110), both in clinical trials for ...
02-02 21:05
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics provided an update on its activities for Q2 FY26, highlighting advancements in its MSA program, Phase 2 data strengthening, and planning for a pivotal Phase 3 trial. The company presented additional analyses of the Phase 2 trial at international congresses, including improved efficacy signals for ATH434 at the 75 mg dose. Regulatory planning for an End-of-Phase 2 meeting with the FDA in mid-2026 is progressing, with a focus ...
01-30 12:25
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Radiopharm Theranostics reported interim results from its Phase 2b clinical trial of RAD 101, with 92% of evaluable participants achieving MRI concordance. Additional interim data from Phase 1 trials of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026. The company ended December 2025 with a cash balance of approximately $34.52 million, providing runway into 2027 to advance its pipeline. RAD 202 and RAD 204 showed promising sa...
01-28 12:00
FAST TRACK GROUP's Fast Track Entertainment Signs MOU With Leanbranding To Support Global Growth Of Rising K-Pop Girl Group KIIRAS
FAST TRACK GROUP (NASDAQ:FTRK) ("Fast Track" or the "Company"), a leading entertainment-focused event management and celebrity agency company, announced that Fast Track Entertainment ("FTE") has signed a Memorandum
01-27 22:08
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
BriaCell Therapeutics Corp. announced positive Phase 2 survival data for patients with metastatic breast cancer treated with the Bria-IMT regimen. Nine of 25 patients treated since 2022 remain alive 18-47 months post-enrollment, exceeding benchmarks for standard therapies. No Bria-IMT-related discontinuations were reported, and the regimen continues under US FDA Fast Track Designation. These findings support the potential of Bria-IMT to significa...
01-27 12:30
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
Greenwich LifeSciences reported increased cash reserves through its ATM financing, reaching $12.5 million, which may cover 2026 expenses. CEO Snehal Patel highlighted cost-saving strategies and the success of FLAMINGO-01, a Phase III trial showing an 80% reduction in breast cancer recurrence rates, aligning with Phase IIb results. The trial's open-label data indicates favorable immune responses and safety profiles across HLA types.
01-27 11:00
Adagene Provides Business Update and 2026 Objectives
Adagene Inc. reported unaudited cash of $74.5M as of Dec 31, 2025, providing runway into late 2027. Key 2025 achievements include Phase 1b/2 trial results for muzastotug in MSS CRC, FDA Fast Track designation for muzastotug + pembrolizumab, regulatory alignment with FDA, and initiation of a randomized Phase 2 trial. Strategic partnerships with Sanofi, Third Arc Bio, Exelixis, and ConjugateBio advanced masked antibody therapies. 2026 objectives in...
01-23 13:00
